pharma · Hypertension · Uncontrolled and Resistant Hypertension · MLYS
Mineralys Therapeutics
Mineralys Therapeutics is a pharma organization headquartered in Radnor, USA. It trades on NYSE under ticker MLYS. Primary therapeutic focus areas include Hypertension, Uncontrolled and Resistant Hypertension, Chronic Ki
Radnor, USA HQ
2020 Founded
106 Employees
Public company Type
MLYS · NYSE Ticker
Company details
- Status
- Public
- HQ
- Radnor, USA
- Founded
- 2020
- Employees
- 106
- Programs
- 7
- Drugs
- 6
- Patents
- 0
MLS-101 (Part I)
Phase 2 · small molecule · Hypertension, Renal
MLS-101 (Part I) for Hypertension, Renal is a Phase 2 program (small_molecule) at Mineralys Therapeutics with 1 ClinicalTrials.gov record(s).
Internal code MLS-101-201
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Mineralys Therapeutics
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Hypertension, Renal
- Status
- completed
- Trials
- 1